P53 Aggregation
P53 Aggregation - Related Videos
04:56
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
0 Views •
2025
Hs578T breast cancer cells harboring the p53 V157F mutation exhibit significantly higher Thioflavin T fluorescence compared to MCF7 cells, indicating enhanced protein aggregation. Multipoint fluorescence measurements improve detection accuracy and reliability in identifying β-sheet-rich aggregates, underscoring the importance of aggregation-prone p53 mutations in cancer research and the development of therapeutic strategies.
17:59
Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
0 Views •
Cited by 11 •
2011
In this video we demonstrate a protocol to establish mouse thymic lymphoma cell lines. By following this protocol, we have successfully established several T-cell lines from Atm-/- and p53-/- mice with thymic lymphoma.
10:10
Aggregates for Concrete and Asphaltic Mixes
0 Views •
2023
Source: Roberto Leon, Department of Civil and Environmental Engineering, Virginia Tech, Blacksburg, VA Concrete and asphalt are by far the most common construction materials used today. Concrete is a composite material consisting of cement, water, air, coarse aggregate, and fine aggregates. Fine aggregates are typically sands and coarse aggregates are natural or crushed rocks. Chemical admixtures to modify certain specific properties are also commonly used (i.e., superplasticizers to make the...
10:55
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
0 Views •
Cited by 1 •
2022
The protocol describes a step-by-step method to purify ubiquitinated proteins from mammalian cells using the p53 tumor suppressor protein as an example. Ubiquitinated p53 proteins were purified from cells under stringent nondenaturing and denaturing conditions.
11:57
Methods to Study Changes in Inherent Protein Aggregation with Age in Caenorhabditis elegans
0 Views •
Cited by 7 •
2017
The goal of the method presented here is to explore protein aggregation during normal aging in the model organism C. elegans. The protocol represents a powerful tool to study the highly insoluble large aggregates that form with age and to determine how changes in proteostasis impact protein aggregation.
FAQs
Aggregated p53 can compromise tumor suppression in two connected ways. Misfolding and self-association reduce the pool of properly structured p53 available to bind DNA and activate protective genes. The aggregates may also sequester remaining functional p53 or related proteins, further diminishing coordinated responses that control cell-cycle arrest, DNA repair, senescence, and apoptosis.
Structural destabilization is the central factor identified in the provided context. Specific p53 mutations can alter the protein’s stability, while cellular conditions may further favor misfolding and self-association. These influences help explain why aggregation is not a uniform property of all p53: particular mutations or environments can shift the balance away from functional tetramers toward oligomers and amyloid-like fibrils.
Functional p53 normally forms tetramers that recognize DNA and activate genes involved in several protective responses. Aggregated assemblies represent a different structural state associated with reduced activity and possible sequestration of other proteins. Comparing these states helps researchers connect changes in p53 structure with changes in tumor-suppressive function rather than treating every altered p53 molecule as biologically equivalent.
Research examines how specific p53 mutations and cellular conditions influence misfolding, oligomer formation, and amyloid-like fibril formation, then considers how those changes affect p53 activity. The resulting analysis can link a mutation or condition to weakened DNA-responsive tumor suppression. This mechanistic connection helps clarify how altered p53 contributes to tumor development.
Understanding the process supports several research directions: identifying aggregation inhibitors, developing diagnostic biomarkers, and designing strategies intended to restore p53 function. These applications address different needs. Inhibitors target the aggregation process, biomarkers may help recognize aggregation-related states, and restoration strategies focus on recovering tumor-suppressive activity that has been compromised by structural alteration.
p53 serves as a central defense against cancer because its normal activity can trigger cell-cycle arrest, DNA repair, senescence, and apoptosis. When aggregation reduces that activity or sequesters related proteins, cells may lose coordinated protective responses. Studying mutation-linked aggregation therefore helps explain how particular p53 alterations can weaken tumor suppression and contribute to tumor development.